e-learning
resources
Paris 2018
Monday, 17.09.2018
News on the diagnosis of idiopathic interstitial pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Histopathologic and Molecular Analysis of Idiopathic Pulmonary Fibrosis Lungs from Patients Treated with Pirfenidone or Nintedanib
Y. Zhang (Nanjing, China), K. Jones (SF, United States of America), N. Achtar-Zadeh (SF, United States of America), J. Kukreja (SF, United States of America), P. Wolters (SF, United States of America), (SF, United States of America)
Source:
International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia
Session:
News on the diagnosis of idiopathic interstitial pneumonia
Session type:
Thematic Poster
Number:
2920
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Zhang (Nanjing, China), K. Jones (SF, United States of America), N. Achtar-Zadeh (SF, United States of America), J. Kukreja (SF, United States of America), P. Wolters (SF, United States of America), (SF, United States of America). Histopathologic and Molecular Analysis of Idiopathic Pulmonary Fibrosis Lungs from Patients Treated with Pirfenidone or Nintedanib. 2920
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Prognostic Factors in Patients with Idiopathic Pulmonary Fibrosis; Evaluation using Quantitative CT Analysis of Fibrosis and Emphysema
Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Year: 2019
Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Evaluation of Idiopathic Pulmonary Fibrosis therapies, Pirfenidone and Nintedanib, in a Human Experimental Model of Fibrosis
Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2019
Treatment of Idiopathic Pulmonary Fibrosis
Source: Guideline 2015
Year: 2015
Clinical Features and Prognosis of Acute exacerbation of Connective Tissue Diseases Associated Pulmonary Fibrosis------ Comparision with Idiopathic Pulmonary Fibrosis
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017
Association between Pulmonary Infections and the Prognosis in Patients with Idiopathic Pulmonary Fibrosis
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
A new Humanized Mouse Model for Idiopathic Pulmonary Fibrosis and Effects of Nintedanib Treatment
Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias
Year: 2018
Alveolar Macrophages Produced from Resected Lungs of Patients with Pulmonary Tuberculosis
Source: International Congress 2017 – Microbiology and laboratory techniques to monitor NTM infections
Year: 2017
Clinical Correlates of Physical Activity in Idiopathic Pulmonary Fibrosis (IPF)
Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases
Year: 2019
Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis
Source: International Congress 2014 – ILDs 5
Year: 2014
Modes of Disease Progression in Different Forms of Interstitial Lung Disease with Usual Interstitial Pneumonia Histology in Patients with Idiopathic and Non-idiopathic Etiologies - A Single Center Experience
Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Year: 2019
Sensitivity analyses from the INPULSIS™ trials of nintedanib
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study
Source: International Congress 2014 – IPF and surroundings
Year: 2014
Bacterial Contamination of Home Nebulizers in Children with Cystic Fibrosis and Clinical Implication on the Number of Pulmonary Exacerbations
Source: International Congress 2019 – Infection and inflammation in cystic fibrosis
Year: 2019
Quantitative Assessment of Thoracic Muscles in Patients with Idiopathic pulmonary fibrosis :Relationship with Prognosis
Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia
Year: 2018
Tele-rehabilitation program in Idiopathic Pulmonary Fibrosis
Source: International Congress 2019 – M-health/e-health I
Year: 2019
Molecular Markers of Telomere Dysfunction and Senescence are Common Findings in the Usual Interstitial Pneumonia Pattern of Lung Fibrosis
Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias
Year: 2018
Development Of A Machine Learning Combination With Deep Learning For Diagnosing Idiopathic Pulmonary Fibrosis In Chronic Interstitial Lung Disease
Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020
Diffuse Pulmonary Non-Amyloid Light-Chain Deposition Disease: Phenotypes and Outcome
Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases
Year: 2021
The Effects Of Respiratory Viruses on The Acute Pulmonary Exacerbations In Cystic Fibrosis Patients
Source: International Congress 2019 – Insights into paediatric bronchology
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept